RoB 2: a revised tool for assessing risk of bias in randomised trials

Assessment of risk of bias is regarded as an essential component of a systematic review on the effects of an intervention. The most commonly used tool for randomised trials is the Cochrane risk-of-bias tool. We updated the tool to respond to developments in understanding how bias arises in randomised trials, and to address user feedback on and limitations of the original tool.

• A
  Amgen
• EL
  Eli Lilly and Company
• CF
  CHDI Foundation
• PO
  Patient-Centered Outcomes Research Institute
• WT
  Wellcome Trust
• UH
  University Hospitals Bristol NHS Foundation Trust
• MC
  Medicines Company
• NB
  NIHR Bristol Biomedical Research Centre
• CR
  Cancer Research UK
• NI
  National Institute for Health and Care Research
• DO
  Department of Health and Social Care
• UO
  University of Bristol

  Award: MC_UU_00011/3
• CR
  Canada Research Chairs
• BI
  Biosensors International Group
• NI
  National Institutes of Health
• MR
  Medical Research Council

  Awards: MR/M025209/1, MR/K025643/1, MC_UU_12023/21, MR/L004933/1, MR/K025643/1, MR/L004933/2, MC_UU_00011/3, MC_UU_12023/21, MR/J004855/1, MC_UU_00011/3, MR/S001751/1, MR/K025635/1, MR/L004933/2, MC_UU_00011
• NH
  National Health and Medical Research Council

  Award: 1088535